...
首页> 外文期刊>Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] >Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases.
【24h】

Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases.

机译:患有肿瘤或非肿瘤性胰腺疾病的患者的纯胰液中肿瘤抑制基因的频繁缺失。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: K-ras codon 12 mutation is the most frequent genetic alteration in pancreatic cancer. Sensitivity and specificity of K-ras are not high enough to detect all pancreatic cancers, especially at early stage. This study investigated whether detection of p16 and/or DPC4 deletions along with K-ras mutation in DNA samples could improve the definition of patients at risk of pancreatic cancer. METHODS: K-ras mutations were investigated by sequencing. p16 and DPC4 homozygous deletions were studied using comparative multiplex polymerase chain reaction of DNA in pancreatic juice sampled during endoscopic retrograde pancreatography in 57 patients with either pancreatic cancer (group I, 18 patients), chronic pancreatitis (group II, 20 patients), or nontumoral pancreatobiliary disease (group III, 19 patients). RESULTS: The frequencies of Ki-ras mutations were 61% in group I, 10% in group II, and 10.5% in group III. The frequencies of p16 exon 2 and DPC4 deletions were, respectively, 28 and 36% in group I, 50 and 58% in group II, and 24 and 36% in group III. CONCLUSIONS: The combination of p16 and DPC4 deletions with K-ras mutation does not improve the diagnosis of pancreatic cancer based on K-ras mutation alone. These data suggest that tumor suppressor gene inactivation can occur with a high frequency during nonmalignant pancreatic diseases.
机译:背景/目的:K-ras密码子12突变是胰腺癌中最常见的遗传改变。 K-ras的敏感性和特异性不足以检测所有胰腺癌,尤其是在早期阶段。这项研究调查了检测DNA样本中p16和/或DPC4缺失以及K-ras突变是否可以改善有胰腺癌风险的患者的定义。方法:通过测序研究K-ras突变。使用比较性多聚酶链反应DNA在胰腺内窥镜逆行胰管造影术中采集的胰腺液中DNA的p16和DPC4缺失进行了研究,研究对象是57例胰腺癌(I组,18例),慢性胰腺炎(II组,20例)或非肿瘤患者胰胆疾病(III组,19例)。结果:Ki-ras突变的频率在第一组为61%,第二组为10%,第三组为10.5%。 p16外显子2和DPC4缺失的频率分别在I组为28%和36%,II组为50%和58%,III组为24%和36%。结论:p16和DPC4缺失与K-ras突变的组合不能改善仅基于K-ras突变的胰腺癌的诊断。这些数据表明,在非恶性胰腺疾病中,抑癌基因失活的频率很高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号